Literature DB >> 9721862

Hepatitis B virus X protein transcription activation domains are neither required nor sufficient for cell transformation.

K Gottlob1, S Pagano, M Levrero, A Graessmann.   

Abstract

The ability of the hepatitis B virus (HBV)-encoded X protein (HBx) to coactivate transcription of viral and cellular genes has been implicated in the development of HBV-related liver cancer. To dissect the transformation and the transcription activation properties of HBx, we generated REV2 cell lines expressing the wild-type and different truncated versions of the protein. Full-length HBx-expressing REV-2 cells display an altered morphology and form large colonies in soft agar. A similar transformation efficiency has been obtained with a truncated version of HBx, which contains only the first 50 NH2-terminal amino acids (HBx 1-50). In contrast, HBx mutants that lack the NH2-terminal segment but retain most of the transactivating function, as compared to the full length HBx, were unable to alter the growth characteristic of REV-2 cells. Furthermore, abrogation of full-length HBx transcriptional activation by the insertion of two amino acids (Arg-Pro) at position 68 did not affect REV-2 cells transformation. These results demonstrate that the transactivation activity of HBx is neither essential nor sufficient for tumor promotion.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9721862

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  12 in total

1.  Impact of hepatitis B virus (HBV) x gene mutations on hepatocellular carcinoma development in chronic HBV infection.

Authors:  Jong-Han Lee; Kwang-Hyub Han; Jae Myun Lee; Jeon Han Park; Hyon-Suk Kim
Journal:  Clin Vaccine Immunol       Date:  2011-04-13

Review 2.  Effect of transforming viruses on molecular mechanisms associated with cancer.

Authors:  Tajhal Dayaram; Susan J Marriott
Journal:  J Cell Physiol       Date:  2008-08       Impact factor: 6.384

3.  Direct association and nuclear import of the hepatitis B virus X protein with the NF-kappaB inhibitor IkappaBalpha.

Authors:  R Weil; H Sirma; C Giannini; D Kremsdorf; C Bessia; C Dargemont; C Bréchot; A Israël
Journal:  Mol Cell Biol       Date:  1999-09       Impact factor: 4.272

4.  Hepatitis B virus X protein in the proteasome of mammalian cells: defining the targeting domain.

Authors:  W N Chen; C J Oon; K S Goo
Journal:  Mol Biol Rep       Date:  2001-03       Impact factor: 2.316

5.  Differential effects on apoptosis induction in hepatocyte lines by stable expression of hepatitis B virus X protein.

Authors:  Nicola Fiedler; Ellen Quant; Ludger Fink; Jianguang Sun; Ralph Schuster; Wolfram H Gerlich; Stephan Schaefer
Journal:  World J Gastroenterol       Date:  2006-08-07       Impact factor: 5.742

6.  Duck hepatitis B virus expresses a regulatory HBx-like protein from a hidden open reading frame.

Authors:  S F Chang; H J Netter; E Hildt; R Schuster; S Schaefer; Y C Hsu; A Rang; H Will
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

7.  Sustained activation of mitogen-activated protein kinases and activator protein 1 by the hepatitis B virus X protein in mouse hepatocytes in vivo.

Authors:  R Nijhara; S S Jana; S K Goswami; A Rana; S S Majumdar; V Kumar; D P Sarkar
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

8.  Transformation of human liver L-O2 cells mediated by stable HBx transfection.

Authors:  Wei-ying Zhang; Na Cai; Li-hong Ye; Xiao-dong Zhang
Journal:  Acta Pharmacol Sin       Date:  2009-07-06       Impact factor: 6.150

9.  The viral transactivator HBx protein exhibits a high potential for regulation via phosphorylation through an evolutionarily conserved mechanism.

Authors:  Sergio Hernández; Mauricio Venegas; Javier Brahm; Rodrigo A Villanueva
Journal:  Infect Agent Cancer       Date:  2012-10-18       Impact factor: 2.965

10.  Differential functions of C- and N-terminal hepatitis B x protein in liver cells treated with doxorubicin in normoxic or hypoxic condition.

Authors:  Davor Kin-Fan Chau; George Gong Chen; Haitao Zhang; Billy Cheuk Sing Leung; Sukying Chun; Paul Bo-San Lai
Journal:  PLoS One       Date:  2012-11-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.